.png){kind=icon}
.png){kind=icon}
Return
Ultrasound for the determination of appropriate needle length for intragluteal injection of long-acting rilpivirine–cabotegravir
.png){kind=icon}
PRE
AI
C
M
N
C
DOI：10.1111/hiv.70272.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Long-acting (LA) intramuscular injections of cabotegravir (CAB) and rilpivirine (RPV) are an effective maintenance therapy for people living with HIV who are virologically suppressed. However, virological failures (VFs) have been reported, often associated with elevated body mass index (BMI), potentially due to inadequate intramuscular drug delivery. Current recommendations mainly rely on BMI to guide needle length selection and do not routinely incorporate imaging techniques. Furthermore, they do not recommend the use of ultrasound as an investigative tool in cases of LA treatment failure.
Keywords:
anti-HIV agents
cabotegravir
HIV
intramuscular injections
rilpivirine
ultrasonography
Journal
IF:
3.2
Papers:
301
Citations:
3.0K